ISU Abxis announced on the 25th that it disclosed the development progress of its Alzheimer's treatment (ISU203) at the Alzheimer's Association International Conference (AAIC) held in Amsterdam, Netherlands, from the 16th to the 20th.
Earlier, ISU Abxis presented animal experiment results on the efficacy and mechanism of action (MoA) of 'ISU203' twice during the first half of this year at Keystone Symposia, a global life sciences conference, and the NDS conference in the field of neurological diseases.
The AAIC presentation was conducted with a focus on networking to find partners, accompanied by a dedicated overseas Business Development (BD) team for the full-scale commercialization of ISU203.
Conference attendees showed interest in ISU203's mechanism of action, which indirectly alleviates neuroinflammation by suppressing systemic inflammation. They highly evaluated the in vivo efficacy that improved cognitive function by removing amyloid beta plaques through activation of microglia phagocytosis.
Other treatments directly targeting amyloid beta commonly exhibit ARIA (Amyloid-related imaging abnormalities) side effects. ISU203 barely crosses the blood-brain barrier, which is expected to increase the likelihood of success by avoiding such issues.
Meetings with representatives from over ten global pharmaceutical companies and academic researchers during the conference provided an opportunity to share the development progress of ISU203. The company introduced that global big pharma companies such as Sanofi-Aventis and Merck Sharp & Dohme Corp directly visited ISU Abxis' poster, showing high interest in ISU203's unique mechanism of action and in vivo (animal experiment) results. It was reported that this became a venue for ongoing additional research discussions.
ISU Abxis began non-clinical trials of ISU203 last year and is currently conducting GLP-Tox (toxicity tests) on monkeys and rats. A company official stated, "No specific toxicity has been confirmed in the tissue pathology results so far," and added, "There should be no difficulties in successfully completing the non-clinical trials this year."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
